Growth Opportunities and Trends in the G-CSF (Granulocyte Colony Stimulating Factors) Market: Key Insights for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the g-csf (granulocyte colony stimulating factors) market?
The market for G-CSF (granulocyte colony stimulating factors) has consistently expanded over the past few years. It’s projected to rise from $5.5 billion in 2024 to $5.72 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.9%. Factors contributing to this growth during the historic period include a rise in cancer incidence, robust economic development in emerging markets, escalated spending on healthcare, an upsurge in pharmaceutical research & development expenditure, and government initiatives.
What will be the g-csf (granulocyte colony stimulating factors) market size in the future?
The geopolymer market is slated to experience substantial expansion in the upcoming years, reaching a staggering $41.71 billion by 2029 with a compound annual growth rate (CAGR) of 28.2%. Influences driving this growth during the forecast period are expected to be advancements in the construction sector, improvements in production methods, widespread urbanization and infrastructure projects, along with increased partnerships within the industry and dedication to innovation. Key trends to look out for during the forecast period encompass the use of geopolymers in eco-friendly packaging, its integration within the aerospace industry, initiatives towards standardization and certification, geopolymer concrete usage in earthquake-prone regions and market broadening in evolving economies.
Get your g-csf (granulocyte colony stimulating factors) market report here!
https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report
What main drivers are fueling expansion in the g-csf (granulocyte colony stimulating factors) market?
One significant driver of growth in the G-CSF (granulocyte colony stimulating factor) market is the escalating occurrence of cancer. Globally, cancer consistently ranks as the second most common cause of death, with one in six fatalities attributed to it. For example, data from the American Cancer Society, a US-based organization committed to eradicating cancer, indicates that January 2023 will see an estimated 1,958,310 new cancer diagnoses and 609,820 cancer-related deaths in the United States. G-CSF represents a category of growth factors instrumental in generating white blood cells in the bone marrow, thereby lessening the potential for infection and sepsis. It considerably aids in the recovery of cancer patients and lowers the mortality rate ensuing from chemotherapy-induced neutropenia. Moreover, it has proven effective in curtailing infections after specific cancer treatments. Consequently, the mounting incidence of cancer will likely propel the expansion of the G-CSF market.
What key areas define the segmentation of the global g-csf (granulocyte colony stimulating factors) market?
The G-CSF (granulocyte colony stimulating factors) market covered in this report is segmented –
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies
3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp
Who are the dominant players expanding their reach in the g-csf (granulocyte colony stimulating factors) market?
Major companies operating in the G-CSF (granulocyte colony stimulating factors) market include Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd, BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy’s Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.
How are evolving market trends shaping g-csf (granulocyte colony stimulating factors) Strategies?
In the G-CSF (granulocyte colony stimulating factor) market, companies are zeroing in on strategic partnerships to develop novel products and expand their market presence. Collaborations with other companies, educational institutions, and research bodies have seen an uptick in recent years, often through in or out-licensing agreements. For instance, in 2022, Singapore’s Evive Biotech established an exclusive long-term licensing deal with APOGEPHA, a German pharmaceutical firm, for the sale of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is an innovative G-CSF long-acting fusion protein that does not require pegylation.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3466
Which regions are emerging as leaders in the g-csf (granulocyte colony stimulating factors) market?
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2024. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Colorectal Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report
Thyroid Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report
Hematology Analyzers and Reagents Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
